Skip to main content
. 2017 Aug 10;255(11):2127–2134. doi: 10.1007/s00417-017-3762-2

Fig. 3.

Fig. 3

Distribution of the number of monitoring visits and the number of injections in patients treated with intravitreal Aflibercept for neovascular age-related macular degeneration according to the Observe-and-Plan regimen